Leerink Partners Initiates Coverage On Kazia Therapeutics with Outperform Rating, Announces Price Target of $30
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.
Leerink Partners analyst Andrew Berens initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Outperform rating and announces Price Target of $30.